Q1 EPS Forecast for Bicara Therapeutics Decreased by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Wedbush lowered their Q1 2025 EPS estimates for shares of Bicara Therapeutics in a research note issued on Thursday, March 27th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.33). Wedbush has a “Outperform” rating and a $31.00 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.10) EPS.

Several other analysts have also issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright lifted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Down 2.8 %

NASDAQ BCAX opened at $12.66 on Monday. The company has a 50-day moving average price of $13.07 and a 200-day moving average price of $17.76. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds have recently modified their holdings of the company. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $25,000. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 67.1% in the 4th quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock worth $12,368,000 after buying an additional 285,000 shares in the last quarter. Wexford Capital LP bought a new stake in Bicara Therapeutics during the fourth quarter valued at about $348,000. Red Tree Management LLC purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at about $55,230,000. Finally, Nuveen Asset Management LLC purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at about $436,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.